Hyperkalemia caused by Qingfei Paidu decoction(清肺排毒汤) in a patient with novel coronavirus pneumonia
10.3760/cma.j.cn114015-20200309-00240
- VernacularTitle:清肺排毒汤致新型冠状病毒肺炎患者高钾血症
- Author:
Maozhi HAN
1
;
Shasha LI
;
Jing LI
;
Xianchao LI
;
Linlin GAO
;
Yan LU
;
Ziyu ZHOU
Author Information
1. 陆军第八十集团军医院药剂科，山东省潍坊市 261021
- Publication Type:Journal Article
- Keywords:
Coronavirus infections;
Hyperkalemia;
Medicine, Chinese traditional;
Qingfei Paidu decoction (清肺排毒汤)
- From:
Adverse Drug Reactions Journal
2020;22(6):375-376
- CountryChina
- Language:Chinese
-
Abstract:
A 23-year-old male patient received moxifloxacin, recombinant human interferon α-2b for injection, and lopinavir and ritonavir for 7 days for novel coronavirus pneumonia. There was no abnor-malityof serum potassium. Moxifloxacin was stopped, Qingfei Paidu decoction(清肺排毒汤) was given, and then the patient′s serum potassium began to rise. On day 10 after taking the decoction, laboratory tests showed serum potassium 5.7 mmol/L and the patient was diagnosed with hyperkalemia. Insulin injection 4 U diluted to 5% glucose injection 250 ml was given once by IV infusion, and then the serum potassium decreased to 5.0 mmol/L 6 hours later and 4.6 mmol/L 2 days later. After 5 days, the serum potassium rose again and finally to 5.4 mmol/L on day 17 after taking the decoction. Insulin was given once that day and 2 days later once daily according to the previous method. Then the serum potassium decreased and did not rise again. The patient recovered from novel coronavirus pneumonia and was discharged on day 28 after hospitalization.
